Thursday, May 13, 2010
Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations (South Africa)
Note: small study (Caucasian); stomach cancer link/BRCA2 (?)
"Stomach cancer prevalence was significantly elevated in the BRCA2-positive families compared with the general population."
Note: this is an issue discussed widely in the recent past (inexpensive/profit/lack of)
Discussing Complementary Therapy Use With Early-Stage Breast Cancer Patients: Exploring the Communication Gap
"These findings indicate that doctors require further education about CAM therapies and supplements as well as guidance in how to raise and effectively discuss CAM issues with concern for their safety while balancing respect for the patients’ beliefs."
abstract: Selenium or No Selenium--That Is the Question in Tumor Patients: A New Controversy -- Integrative Cancer Therapies
What is RNA interference?
RNA interference (RNAi) is a natural process that cells use to turn down, or silence, the activity of specific genes.
Discovered in 1998, RNAi has taken the biomedical community by storm. Researchers quickly capitalized on the discovery and developed RNAi into a powerful research tool that is now used in thousands of labs worldwide.
How does RNAi work?
RNAi works by destroying the molecular messengers that carry information coded in genes to the cell’s protein factories. These messengers, called messenger RNAs (mRNAs), carry out a critical function, without which a gene is essentially inactive.
How can I find out more about RNAi?
See the RNAi section of our Extras on Newsmaking Research page at http://www.nigms.nih.gov/News/Extras/default.htm#rnai.
Epithelial Ovarian Cancer Clinical Trial: A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women [Conditions: Epithelial Ovarian Cancer; Interventions
Epithelial Ovarian Cancer Clinical Trial:
Official Title: “A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women”
The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.